S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:THTX

Theratechnologies Stock Forecast, Price & News

$3.07
-0.07 (-2.23 %)
(As of 03/8/2021 04:30 PM ET)
Add
Compare
Today's Range
$3.02
Now: $3.07
$3.25
50-Day Range
$2.20
MA: $2.68
$3.51
52-Week Range
$1.33
Now: $3.07
$3.57
Volume191,019 shs
Average Volume806,010 shs
Market Capitalization$288.09 million
P/E RatioN/A
Dividend YieldN/A
Beta1.79
Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. It offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. The company's pipeline products include F8 Formulation that could be used for the treatment of HIV-associated lipodystrophy; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was founded in 1993 and is headquartered in Montreal, Canada.
Theratechnologies logo

Headlines

Theratechnologies Inc.
December 31, 2020 |  barrons.com
Theratechnologies CCO resigns
November 3, 2020 |  seekingalpha.com
Theratechnologies down 4% on Q3 earnings
October 15, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:THTX
CUSIPN/A
CIKN/A
Phone514-336-7800
Employees42
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$63.22 million
Book Value$0.32 per share

Profitability

Net Income$-12,500,000.00

Miscellaneous

Market Cap$288.09 million
Next Earnings Date4/13/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.10 out of 5 stars

Medical Sector

954th out of 1,971 stocks

Pharmaceutical Preparations Industry

452nd out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$3.07
-0.07 (-2.23 %)
(As of 03/8/2021 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive THTX News and Ratings via Email

Sign-up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Theratechnologies (NASDAQ:THTX) Frequently Asked Questions

Is Theratechnologies a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Theratechnologies stock.
View analyst ratings for Theratechnologies
or view top-rated stocks.

What stocks does MarketBeat like better than Theratechnologies?

Wall Street analysts have given Theratechnologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Theratechnologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Theratechnologies?

Theratechnologies saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 466,600 shares, an increase of 34.5% from the January 28th total of 346,900 shares. Based on an average daily volume of 533,900 shares, the short-interest ratio is presently 0.9 days. Approximately 0.6% of the shares of the company are sold short.
View Theratechnologies' Short Interest
.

When is Theratechnologies' next earnings date?

Theratechnologies is scheduled to release its next quarterly earnings announcement on Tuesday, April 13th 2021.
View our earnings forecast for Theratechnologies
.

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc. (NASDAQ:THTX) announced its earnings results on Thursday, February, 25th. The company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). Theratechnologies had a negative trailing twelve-month return on equity of 135.78% and a negative net margin of 37.22%.
View Theratechnologies' earnings history
.

How has Theratechnologies' stock price been impacted by Coronavirus (COVID-19)?

Theratechnologies' stock was trading at $2.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, THTX stock has increased by 42.0% and is now trading at $3.11.
View which stocks have been most impacted by COVID-19
.

What guidance has Theratechnologies issued on next quarter's earnings?

Theratechnologies updated its FY 2020 Pre-Market earnings guidance on Thursday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $65.8-66.1 million.

What price target have analysts set for THTX?

5 equities research analysts have issued twelve-month target prices for Theratechnologies' shares. Their forecasts range from $2.00 to $11.00. On average, they anticipate Theratechnologies' stock price to reach $7.13 in the next year. This suggests a possible upside of 129.1% from the stock's current price.
View analysts' price targets for Theratechnologies
or view top-rated stocks among Wall Street analysts.

Who are Theratechnologies' key executives?

Theratechnologies' management team includes the following people:
  • Mr. Philippe Dubuc MBA, Sr. VP & CFO (Age 54)
  • Dr. Christian Marsolais, Sr. VP & Chief Medical Officer (Age 58)
  • Mr. Conor M. Walshe, Gen. Mang. of Theratechnologies Europe Limited (Age 48)
  • Mr. Paul Lévesque, Pres, CEO & Director (Age 57)
  • Leah Gibson, Sr. Director of Investor Relations
  • Mr. Jocelyn Lafond, VP of Legal Affairs & Corp. Sec. (Age 53)
  • Mr. Denis Boucher B.A., L.L.B., VP of Communications & Corp. Affairs (Age 55)

Who are some of Theratechnologies' key competitors?

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Citius Pharmaceuticals (CTXR), Great Panther Mining (GPL), TherapeuticsMD (TXMD), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), ChromaDex (CDXC), Caladrius Biosciences (CLBS) and Chimerix (CMRX).

What is Theratechnologies' stock symbol?

Theratechnologies trades on the NASDAQ under the ticker symbol "THTX."

Who are Theratechnologies' major shareholders?

Theratechnologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Worth Venture Partners LLC (0.16%), Renaissance Technologies LLC (0.14%), Fisher Asset Management LLC (0.04%), Inspire Advisors LLC (0.04%), OneAscent Wealth Management LLC (0.01%) and Cambridge Investment Research Advisors Inc. (0.01%).

Which institutional investors are selling Theratechnologies stock?

THTX stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, and Cambridge Investment Research Advisors Inc..

Which institutional investors are buying Theratechnologies stock?

THTX stock was bought by a variety of institutional investors in the last quarter, including Worth Venture Partners LLC, Renaissance Technologies LLC, Inspire Advisors LLC, OneAscent Wealth Management LLC, and Tranquility Partners LLC.

How do I buy shares of Theratechnologies?

Shares of THTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Theratechnologies' stock price today?

One share of THTX stock can currently be purchased for approximately $3.11.

How much money does Theratechnologies make?

Theratechnologies has a market capitalization of $291.85 million and generates $63.22 million in revenue each year. The company earns $-12,500,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How many employees does Theratechnologies have?

Theratechnologies employs 42 workers across the globe.

What is Theratechnologies' official website?

The official website for Theratechnologies is www.theratech.com.

Where are Theratechnologies' headquarters?

Theratechnologies is headquartered at 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8.

How can I contact Theratechnologies?

Theratechnologies' mailing address is 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8. The company can be reached via phone at 514-336-7800 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.